Zoetis
Zoetis

Zoetis

Pharmaceuticals
WebsiteInvestor RelationsSEC
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

$28.8B

Market Cap • 10/2/2026

2012

(14 years)

Founded

2013

(13 years ago)

IPO

NYSE

Listing Exchange

Flag of United States

United States

Country

S&P500 Participant

Index Composite • 2026

Valuation

P/B

9,1

P/S

3

P/EBITDA

7,3

P/OCF

10

P/FCF

12,2

P/E

11,5

BVPS

7,6

EPS

6,1

Market Cap

Market Cap

28,8B

EV

36,4B

EV/Revenue

3,8

EV/EBITDA

9,2

EV/EBIT

10,5

Payout

Dividend Per Share

2,1

Dividend Yield

3%

Buyback Yield

12,7%

Total Yield

15,7%

Dividend Yield 5Y

1,6%

Payout

34%

Retained Earnings

14,7B

Profitability

Gross Margin

71,5%

EBITDA Margin

41,5%

EBIT Margin

36,4%

Net Margin

27,5%

D&A/EBITDA

3,2%

R&D/Revenue

7,6%

Capex/Revenue

5,5%

Capex/D&A

108,7%

Capex/OCF

18,2%

SBC/OCF

3,3%

% PPE

26,7%

% Goodwill

18,4%

ROE

64,4%

ROIC

24,8%

Growth

CAGR Revenue 5Y

5,1%

CAGR Op. Income 5Y

5,8%

CAGR Net Income 5Y

6,5%

CAGR EPS 5Y

8,8%

CAGR OCF 5Y

6%

Leverage

N.D./EBITDA

1,9

Debt/Equity

0%

Current Ratio

3,1

Quick Ratio

1,6

Interest Coverage

1455%

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium